Search Clinical Trials in the EU

Duration

>20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

101-120 of 140 trials

Pancreatic Cancer: Durvalumab and Rintatolimod Combination

We are studying a new treatment combining durvalumab and rintatolimod for patients with metastatic pancreatic ductal adenocarcinoma. The goal is to see if this combination is safe and improves survival and quality of life.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational MedicinesGastroenterologyOncology

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyPediatrics

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard MedicinesOncology

Pemphigus: Personalized Treatment Strategy vs. Standard Care

We are studying whether a personalized treatment plan based on specific blood markers can reduce relapse rates in pemphigus patients compared to standard treatment with rituximab and corticosteroids.

Pemphigus Diseases>2 yearsMonitoring phase (IV)>20 visits No Placebo Standard MedicinesDermatologyRheumatology

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Partially RemoteHematologyPediatrics

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visits No Placebo Investigational MedicinesHematologyOncology

Ulcerative Colitis: SAR442970 Study

We are investigating how effective different doses of SAR442970 are for adults with moderate to severe ulcerative colitis. The study aims to see if it can help improve symptoms and overall quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational MedicinesGastroenterology

Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

Idiopathic Thrombocytopenic Purpura (ITP)>2 yearsConfirmation phase (III)>20 visits Investigational Medicines Cost ReimbursementHematologyInternal Medicine

Pulmonary Hypertension: Sotatercept Study

We are investigating the safety and effects of sotatercept in individuals with pulmonary hypertension due to heart failure. This study aims to understand how well the treatment works over time.

Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementCardiologyInternal Medicine

Heart Failure: CDR132L Treatment Study

We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.

Heart Failure with Reduced Ejection Fraction6-12 monthsEfficacy phase (II)>20 visits Partially RemoteCardiologyInternal Medicine

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visits No Placebo Standard Medicines Partially RemoteInternal MedicinePulmonology

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Partially RemoteInternal MedicineNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteRheumatology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOphthalmology

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementEndocrinology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesOncologyPulmonology

Diffuse Large B-Cell Lymphoma: Glofitamab with Gemcitabine and Oxaliplatin

We are studying a new treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma. The focus is on understanding the safety and frequency of cytokine release syndrome with this therapy.

Refractory Diffuse Large B-Cell Lymphoma6-12 monthsEfficacy phase (II)>20 visits Partially RemoteHematologyOncology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementOtolaryngologyPulmonology

Search Clinical Trials in the European Union